Bipolar Disorder Treatment in Pregnancy
For women with bipolar disorder during pregnancy, continue mood stabilizers when clinically necessary, with lithium or lamotrigine as preferred first-line agents, while avoiding valproate entirely due to high teratogenic risk.
Risk-Benefit Framework
The decision to treat bipolar disorder during pregnancy must weigh two competing risks:
- Untreated bipolar disorder: High relapse rates (up to 85% when medications discontinued), increased risk of postpartum psychosis, preterm birth, and maternal/fetal safety concerns
- Medication exposure: Potential teratogenic effects varying significantly by agent
The postpartum period carries the highest risk for mood episodes in women with bipolar disorder, making prophylactic treatment continuation critical 1, 2.
First-Line Treatment Options
Lithium
Lithium remains a reasonable first-line option throughout pregnancy when properly monitored 3, 4, 5.
- Historical concerns overstated: Earlier reports from the 1970s suggested high cardiac malformation risk (Ebstein's anomaly), but recent case-control and cohort studies show this risk is much lower than previously reported 4
- Absolute risk: Cardiac malformations occur in approximately 0.6% of lithium-exposed pregnancies versus 0.18% in unexposed pregnancies
- Critical management requirements:
- Reduce dose to 500 mg/day in first trimester if clinically feasible 6
- Therapeutic drug monitoring essential due to pregnancy-related changes in renal clearance 4, 7
- Monitor lithium levels monthly in first two trimesters, weekly in third trimester
- Temporarily discontinue 24-48 hours before delivery, resume immediately postpartum 5
Lamotrigine
- No increased risk of major congenital malformations 4
- Effective for bipolar depression during pregnancy 6
- Caution: High infant/maternal serum ratio during breastfeeding requires infant monitoring 6
Second-Generation Antipsychotics
Quetiapine and other atypical antipsychotics show no statistically significant increased risk of congenital malformations as a class 4, 8.
- Quetiapine specifically recommended for depression during pregnancy 6
- Exception: Risperidone may slightly increase cardiac malformation risk 4
- Olanzapine and quetiapine have low infant/maternal serum ratios during breastfeeding 6
Medications to Avoid
Valproate (Divalproex)
Absolutely contraindicated in pregnancy 4, 9, 8.
- High teratogenic risk: Neural tube defects (1-2%), craniofacial abnormalities, cardiac defects, genital and musculoskeletal malformations
- Neurodevelopmental impairment in exposed children
- Switch to alternative agents during preconception planning
Carbamazepine
- Conflicting evidence on malformation risk 4
- Generally avoided when safer alternatives available
Treatment Algorithm by Clinical Presentation
Acute Mania During Pregnancy
- First-line: Atypical antipsychotics (quetiapine, olanzapine) or lithium 3, 6
- Second-line: Combination of mood stabilizer plus antipsychotic if monotherapy insufficient
- Severe cases: Consider electroconvulsive therapy (ECT) - appears relatively safe though limited data 4
Bipolar Depression During Pregnancy
- First-line: Quetiapine or lamotrigine 6, 8
- Second-line: Add antidepressant (SSRI: sertraline or paroxetine preferred) to mood stabilizer 3, 6
- Critical caveat: Never use antidepressants as monotherapy - risk of manic switch
- SSRIs preferred over tricyclics
- Alternative: Bright light therapy as medication-sparing option 7
Maintenance Treatment
Continue at least one mood stabilizer throughout pregnancy for women with moderate-to-severe illness or recent episodes 3, 9.
- Maintenance should continue minimum 2 years after last episode 3
- Discontinuation only considered in women with mild illness and no recurrences for 2+ years 6
Preconception Planning
Optimal approach involves achieving several months of mood stability before conception 6, 9.
- Switch from valproate or carbamazepine to lithium or lamotrigine
- Simplify to monotherapy when possible
- Establish lowest effective dose
- Document risk-benefit discussion thoroughly
Postpartum Management
Resume or initiate mood stabilizer immediately after delivery - this is the highest-risk period 6, 1, 2.
- Postpartum psychosis risk: 20-30% in women with bipolar disorder
- Sleep protection crucial - sleep deprivation triggers episodes 2
- Monitor closely for 6+ months including through weaning and return of menstruation 1
Breastfeeding Considerations
Breastfeeding is possible with most bipolar medications, though requires infant monitoring 6, 5.
Lower Risk (Low Infant/Maternal Serum Ratio):
- Valproate (though contraindicated in pregnancy)
- Olanzapine
- Quetiapine
- Sertraline
- Paroxetine
Higher Risk (High Infant/Maternal Serum Ratio):
- Lithium - requires careful consideration and infant monitoring
- Lamotrigine - monitor infant for sedation, poor feeding
For lithium during breastfeeding: Check infant lithium levels, thyroid function, and renal function periodically 5.
Critical Monitoring Parameters
During Pregnancy:
- Lithium levels (adjust for increased renal clearance)
- Fetal growth ultrasounds
- Fetal echocardiography at 18-20 weeks if lithium exposure
- Blood pressure monitoring
- Mood symptom tracking
Postpartum:
- Daily mood monitoring first 2 weeks
- Sleep quantity and quality
- Infant development and feeding
- Medication levels if breastfeeding
Common Pitfalls to Avoid
- Discontinuing all medications due to pregnancy: Leads to high relapse rates and potentially worse outcomes than medication exposure 10, 9
- Using valproate: No justification given superior safety profiles of alternatives
- Antidepressant monotherapy: Risk of manic switch - always combine with mood stabilizer 3
- Inadequate postpartum planning: Highest risk period often undertreated 1, 2
- Failing to adjust lithium dosing: Pregnancy alters pharmacokinetics requiring dose modifications 7, 5